Software as a Medical Device (SaMD) developer Median Technologies (Euronext Growth Paris:ALMDT) announced on Friday that it has secured up to EUR47.5m in funding to support the regulatory filings and commercialisation of its eyonis Lung Cancer Screening (LCS) software in the United States and European Union.

This includes a potential EUR37.5m loan from the European Investment Bank (EIB) and an equity line of up to EUR10m from IRIS Capital Investment. The EIB loan will be made available in tranches subject to the completion of certain milestones.

The funding will enable Median to complete the US FDA 510(k) and EU CE mark filings for eyonis LCS, expected in Q2 2025, and support its commercial launch in the US market in Q4 2025. Median said that it is currently in active discussions with leading US AI diagnostics companies for potential commercialisation partnerships.

The company has also rescheduled the repayment of its 2020 EIB loan to October 2025.